Overcoming Clinical Challenges in BRIC Markets - India
Thomson Reuters Cortellis Competitive Intelligence
4A: In India, the primary driver for clinical trials is cost-savings, which runs upwards of 50 to 60 percent as compared to trials in the U.S. However, government and regulatory rules are changing very quickly, more quickly than foreign pharmaceutical companies can keep up. Guidelines for audio-video recording of informed consent have been implemented, trial registration has been mandated, a call for compulsory accreditation of independent ethics committees has been answered, panels of experts for clinical trial application approval and serious adverse events reviews have been compiled, GCP compliance is being ensured by India’s new clinical trial inspection program, and safety update reports are required to be submitted every six months during the trial. Coupled with lost patent cases by Novartis, Roche, Merck, Gilead, and Pfizer in the country, have led to a decline in trials initiated in India since 2010.
SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
